One recent study showed that SMARCA4 acted as a tumor suppressor by cooperating with p53 loss and Kras activation, and SMARCA4‐mutant tumors were sensitive to inhibition of oxidative phosphorylation [25]. This evidence concerns the gene KRAS and neoplasm.